Powered by HealthTechMovers.com
We added 3 stocks to our Healthcare & Biotech Stock Watchlist today because they are receiving Bullish Sentiment from investors and financial bloggers.
In addition, they are generating positive media buzz and/or have insider trading signals which came to our attention. This list below is subject to change on a daily basis, so please be sure you subscribe to our email newsletter.
Centene, CNC
Summary: Centene Corporation is a well-diversified, multi-national healthcare company that primarily provides a set of services to government sponsored healthcare programs. The company serves the under-insured and uninsured individuals through member-focused services. It is also engaged in providing education and outreach programs to inform and assist members in accessing quality, appropriate healthcare services. Through a diversified product portfolio and expanding geographic reach, Centene continues to deliver results by growing premium and service revenues profitably. The company operates in two segments: Managed Care and Specialty Services. Managed Care - This segment provides health plan coverage to individuals through Government subsidized programs, including Medicaid. Specialty Services - This segment consists of its specialty companies offering diversified healthcare services and products to state programs, correctional facilities, healthcare organizations, employer groups and other commercial organizations.
- Last Price: $63.6
- Price Change: -$1.69, -2.59%
- Yearly Gain: -25.44%
- Market Cap: $35.99B
- P/E Ratio: 32.108
Here are 3rd party ratings for CNC:
- TipRanks.com: Moderate Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 20% (199 out of 250)
What is the sentiment on the street regarding Centene ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: Positive
- Investor Sentiment: Positive
- Hedge Fund signal: Positive
If you are interested in CNC or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on CNC before you decide to make any investment.
Click here for chart >>
Incyte, INCY
Summary: Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland. Incyte's lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2 inhibitor, approved in the United States for the treatment of patients with polycythemia vera ('PV'),who have had an inadequate response to or are intolerant to hydroxyurea. It is also approved for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-PV MF, and post-essential thrombocythemia MF. The drug is also approved in the United States for treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients aged 12 years or older.
- Last Price: $72.26
- Price Change: -$1.23, -1.67%
- Yearly Gain: -5.84%
- Market Cap: $16.39B
- P/E Ratio: 48.291
Here are 3rd party ratings for INCY:
- TipRanks.com: Moderate Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Top 38% (95 out of 250)
What is the sentiment on the street regarding Incyte ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bullish
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: Positive
- Investor Sentiment: Very Positive
- Hedge Fund signal: Very Positive
If you are interested in INCY or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on INCY before you decide to make any investment.
Click here for chart >>
Catalyst Pharma, CPRX
Summary: Catalyst Pharmaceuticals, Inc. is a development-stage biopharmaceutical company focused on the development and commercialization of therapies targeting rare neurological diseases and disorders, like Lambert-Eaton Myasthenic Syndrome (LEMS), epilepsy and Tourette syndrome. Catalyst in-licensed rights to Firdapse (for treating LEMS) from BioMarin Pharmaceutical Inc. for its development and commercialization in the U.S. Firdapse is currently approved in the European Union and in the U.S. for treating of LEMS in adults. The company also plans to file a supplemental new drug application for Firdapse to treat pediatric patients with LEMS.'The company is also strengthening the commercial portfolio of Firdapse. It has already received multiple patents that cover the treatment of all amifampridine metabolizer types within the LEMS patient population.'Apart from Firdapse, the company is working on a generic version of Lundbeck's Sabril, CPP-109, for the treatment of infantile spasms and complex partial seizures.
- Last Price: $16.21
- Price Change: -$0.32, -1.94%
- Yearly Gain: 99.40%
- Market Cap: $1.75B
- P/E Ratio: 22.134
Here are 3rd party ratings for CPRX:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Strong Buy, Top 34% (86 out of 250)
What is the sentiment on the street regarding Catalyst Pharma ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: High
- Insider Signal: Positive
- Investor Sentiment: Positive
- Hedge Fund signal: Positive
If you are interested in CPRX or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on CPRX before you decide to make any investment.
Click here for chart >>
Thanks for reading!
